Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.
Type | Public | |
Founded | 2001 | |
HQ | South San Francisco, CA, US | Map |
Website | fiveprime.com | |
Employee Ratings | More |
USD | |
---|---|
Revenue (Q3, 2020) | 2.0m |
Net income (Q3, 2020) | (26.4m) |
EBIT (Q3, 2020) | (33.1m) |
Market capitalization (1-Mar-2021) | 1.1b |
Closing stock price (1-Mar-2021) | 23.4 |
Cash (30-Sept-2020) | 36.0m |
EV | 1.1b |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 32.5m | 7.6m | 5.8m | 5.3m | 3.3m | 3.0m | 8.4m | 3.4m | 2.0m | |||||||||||||
General and administrative expense | 2.6m | 3.3m | 3.0m | 3.4m | 4.2m | 4.6m | 5.2m | 8.6m | 8.1m | 9.1m | 10.5m | 9.4m | 9.7m | 10.5m | 9.8m | 9.8m | 10.5m | 9.7m | 13.2m | 10.5m | 8.0m | 13.7m |
R&D expense | 8.2m | 8.9m | 11.9m | 9.8m | 11.2m | 13.3m | 24.7m | 18.3m | 22.2m | 23.9m | 33.8m | 41.7m | 42.7m | 43.6m | 33.4m | 44.7m | 31.8m | 29.4m | 26.9m | 18.6m | 12.6m | 21.4m |
Operating expense total | 10.8m | 12.2m | 14.9m | 13.2m | 15.4m | 17.9m | 29.9m | 26.9m | 30.3m | 33.0m | 44.2m | 51.1m | 52.4m | 54.0m | 43.2m | 54.5m | 42.3m | 39.1m | 40.2m | 29.0m | 20.6m | 35.2m |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 77.6m | 11.7m | 13.1m | 13.1m | 14.5m | 19.1m | 37.0m | 133.0m | 38.2m | 56.4m | 47.2m | 59.7m | 36.4m | 65.9m | 52.8m | 64.0m | 29.6m | 38.3m | 48.9m | 67.7m | 58.7m | 36.0m |
Accounts Receivable | 383.0k | 20.1m | 177.0k | 91.0k | 133.0k | 718.0k | 1.7m | 1.8m | 3.4m | 2.3m | 5.9m | 3.8m | 4.4m | 4.3m | 2.7m | 5.0m | 3.4m | 2.6m | 3.7m | 2.2m | 2.2m | 1.5m |
Prepaid Expenses | 866.0k | 1.2m | 1.3m | 1.8m | 3.1m | 2.6m | 5.5m | 6.0m | 6.0m | 7.8m | 8.3m | 8.8m | 8.2m | 9.3m | 7.5m | 6.2m | 10.2m | 13.3m | 7.8m | 3.8m | 5.2m | 3.8m |
Current Assets | 87.9m | 150.2m | 142.0m | 131.8m | 220.3m | 210.7m | 190.5m | 490.6m | 480.1m | 454.0m | 399.2m | 363.3m | 333.4m | 403.0m | 363.0m | 332.9m | 250.5m | 230.0m | 197.5m | 150.3m | 134.5m | 123.3m |
USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|
Net Income | (28.9m) | (37.4m) | 249.6m | (65.7m) | (150.2m) | (140.4m) | (137.2m) |
Depreciation and Amortization | 1.7m | 1.6m | 1.7m | 1.7m | 2.5m | 5.0m | |
Accounts Payable | (209.0k) | 701.0k | 798.0k | (1.6m) | 1.9m | (265.0k) | (72.0k) |
Cash From Operating Activities | (25.3m) | 15.3m | 289.1m | (79.8m) | (112.2m) | (122.5m) | (113.9m) |
USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (21.6m) | (8.6m) | (18.5m) | (25.6m) | (11.0m) | (22.5m) | (46.5m) | (13.0m) | (26.2m) | (45.6m) | (33.4m) | (77.7m) | (121.0m) | (20.4m) | (54.4m) | (101.7m) | (35.4m) | (69.8m) | (105.8m) | (20.1m) | (37.1m) | (63.5m) |
Depreciation and Amortization | 1.3m | 391.0k | 772.0k | 1.2m | 400.0k | 823.0k | 1.3m | 375.0k | 782.0k | 1.2m | 515.0k | 1.1m | 1.7m | 1.2m | 2.5m | 3.7m | 1.3m | 2.7m | 3.9m | 1.3m | 2.0m | 2.7m |
Accounts Payable | 467.0k | (1.0k) | 419.0k | 324.0k | (192.0k) | 257.0k | 469.0k | (874.0k) | (1.2m) | (1.4m) | 473.0k | 987.0k | 2.6m | (406.0k) | 229.0k | 258.0k | 3.2m | 2.3m | 3.0m | (388.0k) | (809.0k) | (759.0k) |
Cash From Operating Activities | (15.7m) | (5.6m) | 6.5m | (3.4m) | (10.6m) | (20.2m) | (44.5m) | (34.1m) | (49.2m) | (64.8m) | (27.9m) | (57.0m) | (84.7m) | (10.6m) | (39.0m) | (69.9m) | (32.7m) | (56.3m) | (84.2m) | (15.1m) | (36.1m) | (51.4m) |
USD | Q3, 2013 |
---|---|
Financial Leverage | 1.4 x |
When was Five Prime Therapeutics founded?
Five Prime Therapeutics was founded in 2001.
Who are Five Prime Therapeutics key executives?
Five Prime Therapeutics's key executives are William R. Ringo, Thomas Civik and Francis Sarena.
How many employees does Five Prime Therapeutics have?
Five Prime Therapeutics has 87 employees.
What is Five Prime Therapeutics revenue?
Latest Five Prime Therapeutics annual revenue is $14.9 m.
What is Five Prime Therapeutics revenue per employee?
Latest Five Prime Therapeutics revenue per employee is $171 k.
Who are Five Prime Therapeutics competitors?
Competitors of Five Prime Therapeutics include Pharming Group, Enara Bio and GreyWolf Therapeutics.
Where is Five Prime Therapeutics headquarters?
Five Prime Therapeutics headquarters is located at 111 Oyster Point Blvd, South San Francisco.
Where are Five Prime Therapeutics offices?
Five Prime Therapeutics has an office in South San Francisco.
How many offices does Five Prime Therapeutics have?
Five Prime Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies